Medical Care

Global Targeted Drugs for NSCLC Market Research Report 2025

This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for NSCLC, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for NSCLC.
The Targeted Drugs for NSCLC market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Targeted Drugs for NSCLC market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Targeted Drugs for NSCLC companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan
Amgen
ARIAD Pharmaceuticals (Takeda)
Beacon Pharma Limited
BeiGene
Biocon
Boehringer-Ingelheim
Celgene Corporation
Drug International Limted
Fujifilm Kyowa Kirin Biologics
Genvio Pharma Limited
Hetero Drugs
ImClone Systems ‎(Eli Lilly)
Incepta Pharmaceuticals
Mylan
Novartis
Pfizer
Reliance Lifesciences
Roche
AstraZeneca
Cipla
Teva
OSI Pharmaceuticals
Glenmark Pharmaceuticals
Natco Pharma
Segment by Type
Target EGFR
Target ALK
Target HER2
Target ROS1
Target BRAF
Target MEK
Target VEGFR2
Target VEGF
Target MET
Segment by Application
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Targeted Drugs for NSCLC company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Drugs for NSCLC Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Target EGFR
1.2.3 Target ALK
1.2.4 Target HER2
1.2.5 Target ROS1
1.2.6 Target BRAF
1.2.7 Target MEK
1.2.8 Target VEGFR2
1.2.9 Target VEGF
1.2.10 Target MET
1.3 Market by Application
1.3.1 Global Targeted Drugs for NSCLC Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Targeted Drugs for NSCLC Market Perspective (2020-2031)
2.2 Global Targeted Drugs for NSCLC Growth Trends by Region
2.2.1 Global Targeted Drugs for NSCLC Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Targeted Drugs for NSCLC Historic Market Size by Region (2020-2025)
2.2.3 Targeted Drugs for NSCLC Forecasted Market Size by Region (2026-2031)
2.3 Targeted Drugs for NSCLC Market Dynamics
2.3.1 Targeted Drugs for NSCLC Industry Trends
2.3.2 Targeted Drugs for NSCLC Market Drivers
2.3.3 Targeted Drugs for NSCLC Market Challenges
2.3.4 Targeted Drugs for NSCLC Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted Drugs for NSCLC Players by Revenue
3.1.1 Global Top Targeted Drugs for NSCLC Players by Revenue (2020-2025)
3.1.2 Global Targeted Drugs for NSCLC Revenue Market Share by Players (2020-2025)
3.2 Global Targeted Drugs for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Targeted Drugs for NSCLC Revenue
3.4 Global Targeted Drugs for NSCLC Market Concentration Ratio
3.4.1 Global Targeted Drugs for NSCLC Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Drugs for NSCLC Revenue in 2024
3.5 Global Key Players of Targeted Drugs for NSCLC Head office and Area Served
3.6 Global Key Players of Targeted Drugs for NSCLC, Product and Application
3.7 Global Key Players of Targeted Drugs for NSCLC, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Drugs for NSCLC Breakdown Data by Type
4.1 Global Targeted Drugs for NSCLC Historic Market Size by Type (2020-2025)
4.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Type (2026-2031)
5 Targeted Drugs for NSCLC Breakdown Data by Application
5.1 Global Targeted Drugs for NSCLC Historic Market Size by Application (2020-2025)
5.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Targeted Drugs for NSCLC Market Size (2020-2031)
6.2 North America Targeted Drugs for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Targeted Drugs for NSCLC Market Size by Country (2020-2025)
6.4 North America Targeted Drugs for NSCLC Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Targeted Drugs for NSCLC Market Size (2020-2031)
7.2 Europe Targeted Drugs for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Targeted Drugs for NSCLC Market Size by Country (2020-2025)
7.4 Europe Targeted Drugs for NSCLC Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Targeted Drugs for NSCLC Market Size (2020-2031)
8.2 Asia-Pacific Targeted Drugs for NSCLC Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2020-2025)
8.4 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Targeted Drugs for NSCLC Market Size (2020-2031)
9.2 Latin America Targeted Drugs for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Targeted Drugs for NSCLC Market Size by Country (2020-2025)
9.4 Latin America Targeted Drugs for NSCLC Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted Drugs for NSCLC Market Size (2020-2031)
10.2 Middle East & Africa Targeted Drugs for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2020-2025)
10.4 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Allergan
11.1.1 Allergan Company Details
11.1.2 Allergan Business Overview
11.1.3 Allergan Targeted Drugs for NSCLC Introduction
11.1.4 Allergan Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.1.5 Allergan Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Targeted Drugs for NSCLC Introduction
11.2.4 Amgen Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.2.5 Amgen Recent Development
11.3 ARIAD Pharmaceuticals (Takeda)
11.3.1 ARIAD Pharmaceuticals (Takeda) Company Details
11.3.2 ARIAD Pharmaceuticals (Takeda) Business Overview
11.3.3 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Introduction
11.3.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.3.5 ARIAD Pharmaceuticals (Takeda) Recent Development
11.4 Beacon Pharma Limited
11.4.1 Beacon Pharma Limited Company Details
11.4.2 Beacon Pharma Limited Business Overview
11.4.3 Beacon Pharma Limited Targeted Drugs for NSCLC Introduction
11.4.4 Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.4.5 Beacon Pharma Limited Recent Development
11.5 BeiGene
11.5.1 BeiGene Company Details
11.5.2 BeiGene Business Overview
11.5.3 BeiGene Targeted Drugs for NSCLC Introduction
11.5.4 BeiGene Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.5.5 BeiGene Recent Development
11.6 Biocon
11.6.1 Biocon Company Details
11.6.2 Biocon Business Overview
11.6.3 Biocon Targeted Drugs for NSCLC Introduction
11.6.4 Biocon Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.6.5 Biocon Recent Development
11.7 Boehringer-Ingelheim
11.7.1 Boehringer-Ingelheim Company Details
11.7.2 Boehringer-Ingelheim Business Overview
11.7.3 Boehringer-Ingelheim Targeted Drugs for NSCLC Introduction
11.7.4 Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.7.5 Boehringer-Ingelheim Recent Development
11.8 Celgene Corporation
11.8.1 Celgene Corporation Company Details
11.8.2 Celgene Corporation Business Overview
11.8.3 Celgene Corporation Targeted Drugs for NSCLC Introduction
11.8.4 Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.8.5 Celgene Corporation Recent Development
11.9 Drug International Limted
11.9.1 Drug International Limted Company Details
11.9.2 Drug International Limted Business Overview
11.9.3 Drug International Limted Targeted Drugs for NSCLC Introduction
11.9.4 Drug International Limted Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.9.5 Drug International Limted Recent Development
11.10 Fujifilm Kyowa Kirin Biologics
11.10.1 Fujifilm Kyowa Kirin Biologics Company Details
11.10.2 Fujifilm Kyowa Kirin Biologics Business Overview
11.10.3 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Introduction
11.10.4 Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.10.5 Fujifilm Kyowa Kirin Biologics Recent Development
11.11 Genvio Pharma Limited
11.11.1 Genvio Pharma Limited Company Details
11.11.2 Genvio Pharma Limited Business Overview
11.11.3 Genvio Pharma Limited Targeted Drugs for NSCLC Introduction
11.11.4 Genvio Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.11.5 Genvio Pharma Limited Recent Development
11.12 Hetero Drugs
11.12.1 Hetero Drugs Company Details
11.12.2 Hetero Drugs Business Overview
11.12.3 Hetero Drugs Targeted Drugs for NSCLC Introduction
11.12.4 Hetero Drugs Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.12.5 Hetero Drugs Recent Development
11.13 ImClone Systems ‎(Eli Lilly)
11.13.1 ImClone Systems ‎(Eli Lilly) Company Details
11.13.2 ImClone Systems ‎(Eli Lilly) Business Overview
11.13.3 ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Introduction
11.13.4 ImClone Systems ‎(Eli Lilly) Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.13.5 ImClone Systems ‎(Eli Lilly) Recent Development
11.14 Incepta Pharmaceuticals
11.14.1 Incepta Pharmaceuticals Company Details
11.14.2 Incepta Pharmaceuticals Business Overview
11.14.3 Incepta Pharmaceuticals Targeted Drugs for NSCLC Introduction
11.14.4 Incepta Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.14.5 Incepta Pharmaceuticals Recent Development
11.15 Mylan
11.15.1 Mylan Company Details
11.15.2 Mylan Business Overview
11.15.3 Mylan Targeted Drugs for NSCLC Introduction
11.15.4 Mylan Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.15.5 Mylan Recent Development
11.16 Novartis
11.16.1 Novartis Company Details
11.16.2 Novartis Business Overview
11.16.3 Novartis Targeted Drugs for NSCLC Introduction
11.16.4 Novartis Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.16.5 Novartis Recent Development
11.17 Pfizer
11.17.1 Pfizer Company Details
11.17.2 Pfizer Business Overview
11.17.3 Pfizer Targeted Drugs for NSCLC Introduction
11.17.4 Pfizer Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.17.5 Pfizer Recent Development
11.18 Reliance Lifesciences
11.18.1 Reliance Lifesciences Company Details
11.18.2 Reliance Lifesciences Business Overview
11.18.3 Reliance Lifesciences Targeted Drugs for NSCLC Introduction
11.18.4 Reliance Lifesciences Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.18.5 Reliance Lifesciences Recent Development
11.19 Roche
11.19.1 Roche Company Details
11.19.2 Roche Business Overview
11.19.3 Roche Targeted Drugs for NSCLC Introduction
11.19.4 Roche Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.19.5 Roche Recent Development
11.20 AstraZeneca
11.20.1 AstraZeneca Company Details
11.20.2 AstraZeneca Business Overview
11.20.3 AstraZeneca Targeted Drugs for NSCLC Introduction
11.20.4 AstraZeneca Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.20.5 AstraZeneca Recent Development
11.21 Cipla
11.21.1 Cipla Company Details
11.21.2 Cipla Business Overview
11.21.3 Cipla Targeted Drugs for NSCLC Introduction
11.21.4 Cipla Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.21.5 Cipla Recent Development
11.22 Teva
11.22.1 Teva Company Details
11.22.2 Teva Business Overview
11.22.3 Teva Targeted Drugs for NSCLC Introduction
11.22.4 Teva Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.22.5 Teva Recent Development
11.23 OSI Pharmaceuticals
11.23.1 OSI Pharmaceuticals Company Details
11.23.2 OSI Pharmaceuticals Business Overview
11.23.3 OSI Pharmaceuticals Targeted Drugs for NSCLC Introduction
11.23.4 OSI Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.23.5 OSI Pharmaceuticals Recent Development
11.24 Glenmark Pharmaceuticals
11.24.1 Glenmark Pharmaceuticals Company Details
11.24.2 Glenmark Pharmaceuticals Business Overview
11.24.3 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Introduction
11.24.4 Glenmark Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.24.5 Glenmark Pharmaceuticals Recent Development
11.25 Natco Pharma
11.25.1 Natco Pharma Company Details
11.25.2 Natco Pharma Business Overview
11.25.3 Natco Pharma Targeted Drugs for NSCLC Introduction
11.25.4 Natco Pharma Revenue in Targeted Drugs for NSCLC Business (2020-2025)
11.25.5 Natco Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Targeted Drugs for NSCLC Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Target EGFR
Table 3. Key Players of Target ALK
Table 4. Key Players of Target HER2
Table 5. Key Players of Target ROS1
Table 6. Key Players of Target BRAF
Table 7. Key Players of Target MEK
Table 8. Key Players of Target VEGFR2
Table 9. Global Targeted Drugs for NSCLC Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Targeted Drugs for NSCLC Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 11. Global Targeted Drugs for NSCLC Market Size by Region (2020-2025) & (US$ Million)
Table 12. Global Targeted Drugs for NSCLC Market Share by Region (2020-2025)
Table 13. Global Targeted Drugs for NSCLC Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 14. Global Targeted Drugs for NSCLC Market Share by Region (2026-2031)
Table 15. Targeted Drugs for NSCLC Market Trends
Table 16. Targeted Drugs for NSCLC Market Drivers
Table 17. Targeted Drugs for NSCLC Market Challenges
Table 18. Targeted Drugs for NSCLC Market Restraints
Table 19. Global Targeted Drugs for NSCLC Revenue by Players (2020-2025) & (US$ Million)
Table 20. Global Targeted Drugs for NSCLC Market Share by Players (2020-2025)
Table 21. Global Top Targeted Drugs for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for NSCLC as of 2024)
Table 22. Ranking of Global Top Targeted Drugs for NSCLC Companies by Revenue (US$ Million) in 2024
Table 23. Global 5 Largest Players Market Share by Targeted Drugs for NSCLC Revenue (CR5 and HHI) & (2020-2025)
Table 24. Global Key Players of Targeted Drugs for NSCLC, Headquarters and Area Served
Table 25. Global Key Players of Targeted Drugs for NSCLC, Product and Application
Table 26. Global Key Players of Targeted Drugs for NSCLC, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Targeted Drugs for NSCLC Market Size by Type (2020-2025) & (US$ Million)
Table 29. Global Targeted Drugs for NSCLC Revenue Market Share by Type (2020-2025)
Table 30. Global Targeted Drugs for NSCLC Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 31. Global Targeted Drugs for NSCLC Revenue Market Share by Type (2026-2031)
Table 32. Global Targeted Drugs for NSCLC Market Size by Application (2020-2025) & (US$ Million)
Table 33. Global Targeted Drugs for NSCLC Revenue Market Share by Application (2020-2025)
Table 34. Global Targeted Drugs for NSCLC Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 35. Global Targeted Drugs for NSCLC Revenue Market Share by Application (2026-2031)
Table 36. North America Targeted Drugs for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. North America Targeted Drugs for NSCLC Market Size by Country (2020-2025) & (US$ Million)
Table 38. North America Targeted Drugs for NSCLC Market Size by Country (2026-2031) & (US$ Million)
Table 39. Europe Targeted Drugs for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 40. Europe Targeted Drugs for NSCLC Market Size by Country (2020-2025) & (US$ Million)
Table 41. Europe Targeted Drugs for NSCLC Market Size by Country (2026-2031) & (US$ Million)
Table 42. Asia-Pacific Targeted Drugs for NSCLC Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 43. Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2020-2025) & (US$ Million)
Table 44. Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2026-2031) & (US$ Million)
Table 45. Latin America Targeted Drugs for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Latin America Targeted Drugs for NSCLC Market Size by Country (2020-2025) & (US$ Million)
Table 47. Latin America Targeted Drugs for NSCLC Market Size by Country (2026-2031) & (US$ Million)
Table 48. Middle East & Africa Targeted Drugs for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 49. Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2020-2025) & (US$ Million)
Table 50. Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2026-2031) & (US$ Million)
Table 51. Allergan Company Details
Table 52. Allergan Business Overview
Table 53. Allergan Targeted Drugs for NSCLC Product
Table 54. Allergan Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 55. Allergan Recent Development
Table 56. Amgen Company Details
Table 57. Amgen Business Overview
Table 58. Amgen Targeted Drugs for NSCLC Product
Table 59. Amgen Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 60. Amgen Recent Development
Table 61. ARIAD Pharmaceuticals (Takeda) Company Details
Table 62. ARIAD Pharmaceuticals (Takeda) Business Overview
Table 63. ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Product
Table 64. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 65. ARIAD Pharmaceuticals (Takeda) Recent Development
Table 66. Beacon Pharma Limited Company Details
Table 67. Beacon Pharma Limited Business Overview
Table 68. Beacon Pharma Limited Targeted Drugs for NSCLC Product
Table 69. Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 70. Beacon Pharma Limited Recent Development
Table 71. BeiGene Company Details
Table 72. BeiGene Business Overview
Table 73. BeiGene Targeted Drugs for NSCLC Product
Table 74. BeiGene Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 75. BeiGene Recent Development
Table 76. Biocon Company Details
Table 77. Biocon Business Overview
Table 78. Biocon Targeted Drugs for NSCLC Product
Table 79. Biocon Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 80. Biocon Recent Development
Table 81. Boehringer-Ingelheim Company Details
Table 82. Boehringer-Ingelheim Business Overview
Table 83. Boehringer-Ingelheim Targeted Drugs for NSCLC Product
Table 84. Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 85. Boehringer-Ingelheim Recent Development
Table 86. Celgene Corporation Company Details
Table 87. Celgene Corporation Business Overview
Table 88. Celgene Corporation Targeted Drugs for NSCLC Product
Table 89. Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 90. Celgene Corporation Recent Development
Table 91. Drug International Limted Company Details
Table 92. Drug International Limted Business Overview
Table 93. Drug International Limted Targeted Drugs for NSCLC Product
Table 94. Drug International Limted Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 95. Drug International Limted Recent Development
Table 96. Fujifilm Kyowa Kirin Biologics Company Details
Table 97. Fujifilm Kyowa Kirin Biologics Business Overview
Table 98. Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Product
Table 99. Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 100. Fujifilm Kyowa Kirin Biologics Recent Development
Table 101. Genvio Pharma Limited Company Details
Table 102. Genvio Pharma Limited Business Overview
Table 103. Genvio Pharma Limited Targeted Drugs for NSCLC Product
Table 104. Genvio Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 105. Genvio Pharma Limited Recent Development
Table 106. Hetero Drugs Company Details
Table 107. Hetero Drugs Business Overview
Table 108. Hetero Drugs Targeted Drugs for NSCLC Product
Table 109. Hetero Drugs Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 110. Hetero Drugs Recent Development
Table 111. ImClone Systems ‎(Eli Lilly) Company Details
Table 112. ImClone Systems ‎(Eli Lilly) Business Overview
Table 113. ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Product
Table 114. ImClone Systems ‎(Eli Lilly) Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 115. ImClone Systems ‎(Eli Lilly) Recent Development
Table 116. Incepta Pharmaceuticals Company Details
Table 117. Incepta Pharmaceuticals Business Overview
Table 118. Incepta Pharmaceuticals Targeted Drugs for NSCLC Product
Table 119. Incepta Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 120. Incepta Pharmaceuticals Recent Development
Table 121. Mylan Company Details
Table 122. Mylan Business Overview
Table 123. Mylan Targeted Drugs for NSCLC Product
Table 124. Mylan Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 125. Mylan Recent Development
Table 126. Novartis Company Details
Table 127. Novartis Business Overview
Table 128. Novartis Targeted Drugs for NSCLC Product
Table 129. Novartis Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 130. Novartis Recent Development
Table 131. Pfizer Company Details
Table 132. Pfizer Business Overview
Table 133. Pfizer Targeted Drugs for NSCLC Product
Table 134. Pfizer Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 135. Pfizer Recent Development
Table 136. Reliance Lifesciences Company Details
Table 137. Reliance Lifesciences Business Overview
Table 138. Reliance Lifesciences Targeted Drugs for NSCLC Product
Table 139. Reliance Lifesciences Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 140. Reliance Lifesciences Recent Development
Table 141. Roche Company Details
Table 142. Roche Business Overview
Table 143. Roche Targeted Drugs for NSCLC Product
Table 144. Roche Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 145. Roche Recent Development
Table 146. AstraZeneca Company Details
Table 147. AstraZeneca Business Overview
Table 148. AstraZeneca Targeted Drugs for NSCLC Product
Table 149. AstraZeneca Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 150. AstraZeneca Recent Development
Table 151. Cipla Company Details
Table 152. Cipla Business Overview
Table 153. Cipla Targeted Drugs for NSCLC Product
Table 154. Cipla Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 155. Cipla Recent Development
Table 156. Teva Company Details
Table 157. Teva Business Overview
Table 158. Teva Targeted Drugs for NSCLC Product
Table 159. Teva Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 160. Teva Recent Development
Table 161. OSI Pharmaceuticals Company Details
Table 162. OSI Pharmaceuticals Business Overview
Table 163. OSI Pharmaceuticals Targeted Drugs for NSCLC Product
Table 164. OSI Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 165. OSI Pharmaceuticals Recent Development
Table 166. Glenmark Pharmaceuticals Company Details
Table 167. Glenmark Pharmaceuticals Business Overview
Table 168. Glenmark Pharmaceuticals Targeted Drugs for NSCLC Product
Table 169. Glenmark Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 170. Glenmark Pharmaceuticals Recent Development
Table 171. Natco Pharma Company Details
Table 172. Natco Pharma Business Overview
Table 173. Natco Pharma Targeted Drugs for NSCLC Product
Table 174. Natco Pharma Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)
Table 175. Natco Pharma Recent Development
Table 176. Research Programs/Design for This Report
Table 177. Key Data Information from Secondary Sources
Table 178. Key Data Information from Primary Sources
Table 179. Authors List of This Report


List of Figures
Figure 1. Targeted Drugs for NSCLC Picture
Figure 2. Global Targeted Drugs for NSCLC Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Targeted Drugs for NSCLC Market Share by Type: 2024 VS 2031
Figure 4. Target EGFR Features
Figure 5. Target ALK Features
Figure 6. Target HER2 Features
Figure 7. Target ROS1 Features
Figure 8. Target BRAF Features
Figure 9. Target MEK Features
Figure 10. Target VEGFR2 Features
Figure 11. Target VEGF Features
Figure 12. Target MET Features
Figure 13. Global Targeted Drugs for NSCLC Market Size by Application (2020-2031) & (US$ Million)
Figure 14. Global Targeted Drugs for NSCLC Market Share by Application: 2024 VS 2031
Figure 15. Squamous Cell Carcinoma of NSCLC Case Studies
Figure 16. Adenocarcinoma of NSCLC Case Studies
Figure 17. Large Cell Carcinoma of NSCLC Case Studies
Figure 18. Targeted Drugs for NSCLC Report Years Considered
Figure 19. Global Targeted Drugs for NSCLC Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 20. Global Targeted Drugs for NSCLC Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 21. Global Targeted Drugs for NSCLC Market Share by Region: 2024 VS 2031
Figure 22. Global Targeted Drugs for NSCLC Market Share by Players in 2024
Figure 23. Global Top Targeted Drugs for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for NSCLC as of 2024)
Figure 24. The Top 10 and 5 Players Market Share by Targeted Drugs for NSCLC Revenue in 2024
Figure 25. North America Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. North America Targeted Drugs for NSCLC Market Share by Country (2020-2031)
Figure 27. United States Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Canada Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Europe Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Europe Targeted Drugs for NSCLC Market Share by Country (2020-2031)
Figure 31. Germany Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. France Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. U.K. Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Italy Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Russia Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Nordic Countries Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Targeted Drugs for NSCLC Market Share by Region (2020-2031)
Figure 39. China Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Japan Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. South Korea Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Southeast Asia Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. India Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Australia Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Latin America Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Latin America Targeted Drugs for NSCLC Market Share by Country (2020-2031)
Figure 47. Mexico Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Brazil Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Middle East & Africa Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Middle East & Africa Targeted Drugs for NSCLC Market Share by Country (2020-2031)
Figure 51. Turkey Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Saudi Arabia Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. UAE Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. Allergan Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 55. Amgen Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 56. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 57. Beacon Pharma Limited Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 58. BeiGene Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 59. Biocon Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 60. Boehringer-Ingelheim Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 61. Celgene Corporation Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 62. Drug International Limted Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 63. Fujifilm Kyowa Kirin Biologics Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 64. Genvio Pharma Limited Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 65. Hetero Drugs Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 66. ImClone Systems ‎(Eli Lilly) Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 67. Incepta Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 68. Mylan Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 69. Novartis Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 70. Pfizer Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 71. Reliance Lifesciences Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 72. Roche Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 73. AstraZeneca Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 74. Cipla Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 75. Teva Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 76. OSI Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 77. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 78. Natco Pharma Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies